Yazar "Yilmaz M.I." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    The effect of leptin on adrenal glands in rats with streptozotocin-induced diabetes: An experimental study
    (2007) Ergin K.; Aktug H.; Başaloglu H.; Başaloglu H.K.; Yilmaz M.I.; Turgut M.
    OBJECTIVE: To determine the cross-section area of adrenal medulla and the percentage of Ki-67 (a proliferation marker) of the adrenal gland in diabetic rats after leptin injection. STUDY DESIGN: Twenty-nine male Wistar rats were randomly divided into 3 groups: control (C) group (n = 9), diabetes mellitus (DM) group (n = 10) and leptin-injected diabetes mellitus (DM+L) group (n = 10). Experimental DM was induced by a single intraperitoneal dose of streptozotocin (40 mg/kg). After this, leptin (100 µg/kg) was injected subcutaneously for a period of 2 weeks in the diabetic group. RESULTS: An atrophy of adrenal medulla in the DM group was observed, and this atrophy returned to normal morphology after injection of leptin. In addition, an increase in the Ki-67 percentage was demonstrated in the zona reticularis layers in the DM+L group. CONCLUSION: Our study indicated that leptin stimulates the sympathoadrenal system and the androgen producing adrenal cortex in DM rats. © Science Printers and Publishers, Inc.
  • Küçük Resim Yok
    Öğe
    Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model
    (2006) Yilmaz M.I.; Korkmaz A.; Kaya A.; Sonmez A.; Caglar K.; Topal T.; Eyileten T.; Yenicesu M.; Acikel C.; Oter S.; Yaman H.; Aktug H.; Oguz Y.; Vural A.; Ikizler T.A.
    Background/Aims: Proteinuria is associated with oxidant stress and inflammation. Hyperbaric oxygen (HBO) treatment has anti-inflammatory and anti-oxidant effects. The aim of the study was to investigate the benefits of HBO treatment on an experimental nephrotic syndrome model. Methods: 50 male Sprague-Dawley rats weighing 255 ± 39 g were housed. Forty rats were injected 6 mg/kg adriamycin into tail veins under anesthesia to induce nephrosis, while 10 rats were spared as sham control. After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2.8 atmosphere absolute, 90 min/day), HBO + losartan (n = 10) and vehicle (n = 10). Protein carbonyl (PCO), superoxide dismutase (SOD) and glutathione peroxidase (GPx) were analyzed from tissue specimens. Biochemical markers were studied from venous samples and 24-hour urine was collected for proteinuria. The surviving animals at 12 weeks (vehicle group (n = 6), HBO (n = 6), losartan (n = 8), HBO + losartan (n = 10) were sacrificed. Glomerular sclerosis, tubulointerstitial and blood vessel changes were determined by semiquantitative scoring. Results: The PCO levels increased (p < 0.001), and the GPx and SOD levels decreased (p < 0.001 for both) in the nephrotic rats. In losartan and HBO groups GPx levels increased (p = 0.001, p = 0.002 respectively), but PCO and SOD levels did not change. The combination of HBO with losartan significantly increased the GPx and SOD levels (p = 0.001 for both) and decreased PCO levels (p = 0.005). HBO but not losartan significantly reduced proteinuria (p < 0.001). The combination of HBO and losartan reduced proteinuria better than the single losartan regime (p < 0.001). The effect of the combination was also noticed on the histological examination of the kidneys. The activities, appetites, weight gains, and improvement of edema were better in the HBO combined with losartan regime. Conclusions: These results indicate that the addition of HBO therapy to a conventional regime, angiotensin receptor blockers, has significant benefits in the management of proteinuria. Future clinical studies are needed to elucidate the role of HBO and other antioxidant strategies in the treatment of proteinuria. Copyright © 2006 S. Karger AG.
  • Küçük Resim Yok
    Öğe
    A novel player in atherosclerotic diseases in renal patients: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
    (2013) Güngor O.; Yilmaz M.I.; Toz H.
    Cardiovascular disease is common in patients with chronic kidney disease. Atherosclerosis has a very important role in pathogenesis of cardiovascular diseases. Tumor Necrosis factor- Like Weak Inducer of Apoptosis (TWEAK) is a glycoprotein that belongs to the TNF superfamily. TWEAK plays important roles in cellular proliferation, growth, migration, osteoclastogenesis, angiogenesis and apoptosis. In the recent years, TWEAK has been suggested to have a role in atherosclerosis. While it is known that TWEAK levels are decreased in patient with renal failure, its association with atherosclerosis is not well-defi ned. This review focuses on the association of TWEAK with atherosclerosis in patients with renal patients.